BXRX / Baudax Bio, Inc.'s (BXRX) CEO Gerri Henwood on Q1 2022 Results - Earnings Call Transcript

As the market attempted to recover from a recent series of disappointing performances, biotechnology firm Baudax Bio (NASDAQ: BXRX ) represented a dra more_horizontal

Shares of Baudax Bio added 80% after it announced its lead clinical candidate targeting Hemophilia A with inhibitors has been awarded orphan drug stat more_horizontal

Baudax Bio (BXRX) soars on the acquisition of a private company, TeraImmune. The acquisition will help advance novel cell therapies for autoimmune dis more_horizontal

Against a broadly positive backdrop due to cooling inflation data, Baudax Bio (NASDAQ: BXRX ) nevertheless managed to resoundingly steal the spotlight more_horizontal

Shares of Baudax Bio BXRX, -1.85% jumped 25% premarket on Friday after the company announced the acquisition of TeraImmune, a privately held biotech d more_horizontal

New data from Baudax's (BXRX) study on BX1000 confirms greater comparability of the highest dose of the candidate to the standard dose of rocuronium a more_horizontal

Baudax Bio (NASDAQ: BXRX ) stock is falling hard on Thursday after the pharmaceutical company announced a public stock offering. Baudax Bio reveals t more_horizontal

Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000. W more_horizontal